Results of a study examining pembrolizumab compared with brentuximab vedotin for treatment of relapsed Hodgkin lymphoma.
Home / Resource Library / Quality of life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma